Search Within

Department of Medicine

Formats
  1. Journal Article (19613)
  2. Meeting Abstract (16046)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22344)
  2. Hematologic Malignancies, Division of (13286)
  3. Center for Hematologic Malignancies (11069)
  4. GSK Faculty (10650)
  5. Survivorship Research (9343)
  6. Division of Subspecialty Medicine (7553)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1112)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2290)
  6. Nature Publishing Group (2119)

More Publishers

Results (39663)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ansamycins inactivate AKT and enhances the anti-tumor effects of paclitaxel
    Meeting Abstract

    Solit, D.; Basso, A.; Munster, P.; Scher, H.; Rosen, N.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer
    Meeting Abstract

    Sabbatini, P.; Brown, J.; Peters, W. A.; Jacobs, A.; Mehdi, A.; Crozier, M. A.; Rivkin, S.; Bolton, M. G.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens
    Meeting Abstract

    Papadimitrakopoulou, V.; Figlin, R.; Garland, L.; von Hoff, D.; Kris, M.; Purdom, M.; Brown, G. L.; Maack, C.; Macpherson, J.; Henner, W. D.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A novel class of pyridopyrimidine tyrosine kinase inhibitors blocks cancer cells in the S-phase of the cell cycle
    Meeting Abstract

    Mizenina, O.; Moasser, M.; Rosen, N.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • 17AAG low target binding affinity and potent whole cell potency: Finding an explanation
    Meeting Abstract

    Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Neckers, L.; Whitesell, L.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR gamma)
    Meeting Abstract

    Budman, D. R.; Schwartz, G. K.; Endres, S.; Welch, M.; O'reilly, E.; Barile-Thiem, B.; Brail, L. H.; De Alwis, D. P.; Cleverly, A.; Weitzman, A.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • A phase I/II study of DX-8951f and gemcitabine in advanced solid tumour malignancies
    Meeting Abstract

    Abou-Alfa, G.; Lenzi, R.; Mani, S.; Schwartz, G.; Maki, R.; Kelsen, D.; Levin, A.; Ackerman, J.; DeJager, R.; O'reilly, E.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Stem cell transplantation (SCT) for the treatment of Fanconi anemia (FA) using a fludarabine (Flu) based cytoreductive regimen and T-cell depleted grafts from unrelated or mismatched related donors
    Meeting Abstract

    Boulad, F.; Auerbach, A. D.; Small, T. N.; Prasad, V.; Torok-Castanza, J.; Casson, A.; Duschock, B.; Collins, N.; Kernan, N. A.; O'Reilly, R. J.
    Blood (2002)

    Fulltext@MSK | Save
  • Comparison of in vitro immune reconstitution and opportunistic infections in adults and children following unmodified unrelated BMT (cBMT)
    Meeting Abstract

    Small, T. N.; Papadopoulos, E. B.; Boulad, F.; Smith, K.; Young, J. W.; Kernan, N. A.; O'Reilly, R. J.
    Blood (2002)

    Fulltext@MSK | Save